kısım 1 temel kalp yetersizliği - Rasim Enar

Kalp Yetersizliği Sendromu 135
CAMİAT: Canadian Amiodarone Myocardial infarction Arrhythmia
Trial. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized
trial of outcome after myocardial infarction in patients
with frequent or repetitive ventricular prematüre depolarizations:
CAMIAT. Canadian Amiodarone Myocardial infarction
Arrhythmia Trial Investigators. Lancet 1997;349(9053):675-
682. Erratum in: Lancet 1997;349(9067):1776.
CAST: Cardiac Arrhythmia Suppression Trial. Echt DS, Liebson
PR, Mitchell LB, et al. Mortality and morbidity in patients
receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia
Suppression Trial. N. Engl. J. Med. 1991;324(12):781-788.
CIBIS-LT: Cardiac Insufficiency Bisoprolol Study II.
CIBIS-2 Investigators. The Cardiac Insufficiency Bisoprolol
Study II (CIBISTI): a randomized trial. Lancet 1999;353(9146):9-
13.
CCS-1: Chinese Cardiac Study
CCS-1 Investigators. Oral captopril versus placebo among
13,634 patients with suspected acute myocardial infarction: interim
report from the Chinese Cardiac Study (CCS-1). Lancet
1995;345(8951):686-687.
CCS-1:Chinese Cardiac Study.
CCS-1 Investigators. Oral captopril versus placebo among
14,962 patients with suspected acute myocardial infarction:
a multicenter, randomized, double-blind, placebo controlled
clinical trial. Chinese Cardiac Study (CCS-1) Collaborative
Group. Chitı. Med. J. (Engl). 1997;110(ll):834-838.
CHARM-Added: Candesartan in Heart Failure Assessment
of Reduction in Mortality and Morbidity Trial-Added.
McMurray JJ, Ostergren J, Swedberg K, et al. CHARM Investigators
and Committees. Effects of candesartan in patients
with chronic heart failure and reduced left-ventricular systolic
function taking angiotensin-converting-enzyme inhibitors: the
CHARM-Added trial. Lancet 2003;362(9386):767-771.
CHARM-Alternative: Candesartan in Heart Failure Assessment
of Reduction in Mortality and Morbidity Trial-Alternative.
Granger CB, McMurray JJ, Yusuf S, et al. CHARM Investigators
and Committees. Effects of candesartan in patients with chronic
heart failure and reduced left-ventricular systolic function
intolerant to angiotensin-converting-enzyme inhibitors: the
CHARM-Alternative trial. Lancet 2003;362(9386):772-776.
CHARM-Overall: Candesartan in Heart Failure Assessment
of Reduction in Mortality and Morbidity Trial-Overall.
Pfeffer MA, Svvedberg K, Granger CB, et al. CHARM Investigators
and Committees. Effects of candesartan on mortality
and morbidity in patients with chronic heart failure: the
CHARM-Overall programme. Lancet 2003;362(9386):759-766.
CHARM-Preserved: Candesartan in Heart Failure Assessment
of Reduction in Mortality and Morbidity Trial-Preserved.
Yusuf S, Pfeffer MA, Swedberg K, et al. CHARM Investigators
and Committees. Effects of candesartan in patients with chronic
heart failure and preserved left-ventricular ejection frac-
tion: the CHARM-Preserved Trial. Lancet 2003;362(9386):777-
781.
CHF-STAT: Congestive Heart Failure Survival Trial of Antiarrhythmic
Therapy.
Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients
with congestive heart failure and asymptomatic ventricular arrhythmia.
Survival Trial of Antiarrhythmic Therapy in Congestive
Heart Failure. N. Engl. J. Med. 1995;333(2):77-82.
CHRISTMAS: Carvedilol Hibernating Reversible Ischaemia
Trial.
Cleland JG, Pennell DJ, Ray SG, Coats AJ, Macfarlane PW,
Murray GD, Mule JD, Vered Z, Lahiri A; Carvediloi Hibernating
Reversible Ischaemia Trial: Marker of success Investigators.
Myocardial viability as a determinant of the ejection
fraction response to carvediloi in patients with heart failure
(CHRISTMAS trial): randomized controlled trial. Lancet
2003;362(9377):14-21.
COMET: Carvedilol Or Metoprolol European Trial. Poole-Wilson
PA, Svvedberg K, Cleland JG, et al. Carvediloi Or Metoprolol
European Trial Investigators. Comparison of carvediloi and
metoprolol on clinical outcomes in patients with chronic heart
failure in the Carvediloi Or Metoprolol European Trial (CO-
MET): randomized controlled trial. Lancet 2003;362(9377):7-13.
COMPANION: Comparison of Medical Therapy, Pacing,
and Defibrillation in Chronic Heart Failure.
Bristovv MR, Saxon LA, Boehmer J, et al. Comparison of Medical
Therapy, Pacing, and Defibrillation in Heart Failure (COM-
PANION) Investigators. Cardiac-resynchronization therapy
with or without an implantable defibrillator in advanced chronic
heart failure. N. Engl. J. Med. 2004;350(21):2140-2150.
CONSENSUS: Cooperative North Scandinavian Enalapril
Survival Study.
The CONSENSUS Trial Study Group. Effects of enalapril on
mortality in severe congestive heart failure. Results of the Cooperative
North Scandinavian Enalapril Survival Study (CON-
SENSUS). N. Engl. ]. Med. 1987;316(23):1429-1435.
COPERNICUS: Carvediloi Prospective Randomized Cumulative
Survival Study.
Packer M, Coats AJ, Fowler MB, et al. Carvediloi Prospective
Randomized Cumulative Survival Study Group. Effect of carvediloi
on survival in severe chronic heart failure. N. Engl. J.
Med. 2001;344(22):1651-1658.
DIG: Digitalis Investigation Group.
The Digitalis Investigation Group. The effect of digoxin on
mortality and morbidity in patients with heart failure. N. Engl.
J. Med. 1997;336(8):525-533.
ECHOES: Echocardiographic Heart of England
Screening Study.
Davies M, Hobbs F, Davis R, et al. Prevalence of
left-ventricular systolic dysfunction and heart failure
in the Echocardiographic Heart of England
Screening study: a population based study. Lancet
2001;358(9280):439^W4.